CRA consultants were commissioned by the European Federation of Pharmaceutical Industries and Associations (EFPIA) to conduct an independent and objective assessment of the impact on the life sciences industry in Europe of a withdrawal of the United Kingdom from the European Union (commonly described as British exit from the EU or “Brexit”). The broad goal of this project was to identify, from both a UK and a European perspective, the positive and negative impact that a change in the relationship might have upon activities along the industry’s value chain.
To read the report, click the link below.
France’s temporary authorisation (ATU) programme: reform implications
The temporary authorisation for use (Autorisation Temporaire d’Utilisation, ATU) programme in France is intended to provide early access to medicines for...